Vertex Pharmaceuticals Heading $600? A Stock Outlook
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Spending reports summarize where money goes and where to cut back. Convert findings into concrete budget adjustments that sustain progress.
19,889 articlesInvestors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Evaxion's Q1 2026 results shed light on how its AI-driven drug discovery model is translating into collaborations and...
A new Girl Scouts survey reveals AI is now a regular companion for girls ages 5-13, often seen as a smarter tutor and...
Visa and Mastercard trade near key price levels as investors reassess growth prospects, margins, and regulatory risk....
As investors scan headlines in June, Comcast's bold $8 billion UK theme park plan stands out. This article explains w...
Anthropic's IPO signals more than one company going public. It underscores a rising demand for AI compute, potentiall...
By late 2025, roughly 12% of U.S. adults were using GLP-1 weight-loss medications, a trend that is quietly trimming g...
Oracle's shares have fallen steeply as AI hype cooled. This article breaks down whether the stock is a value opportun...
Geopolitical shocks have a long echo in the markets. This piece uses 86 years of history to explain how Iran tensions...
A booming demand backdrop for chips collides with sky-high spending. This piece breaks down what Taiwan Semiconductor...
A sweeping real-world study of roughly 600,000 GLP-1 users finds cravings for cigarettes, alcohol, and other addictio...
A recent SEC filing shows Tabor Asset Management increasing its stake in Madison Square Garden Sports, underscoring a...